Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics to treat cancer. Its lead candidate, [225Ac]-FPI-1434, combines the precision targeting of an antibody with the potency of alpha-particle emitting medical isotopes to attack multiple tumor types. Fusion employs a proprietary Fast-Clear™ Linker Technology Platform designed to rapidly clear unbound medical isotopes to expand the therapeutic window and is applying the platform across different classes of molecules. The company is expanding its pipeline through a proprietary protein discovery platform, in-licensing targeting molecules, and forming strategic partnerships. The $105 million Series B financing will be used to advance and broaden its ongoing clinical program, accelerate new radiopharmaceuticals and combination therapy strategies, and support team expansion and partnering efforts. Fusion has operations in Hamilton, Ontario, Canada and Boston, MA.

Total raised

$105M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2019